Vesicular approach of cubosomes, its components, preparation techniques, evaluation and their appraisal for targeting cancer cells

References

• Zugazagoitia J, Guedes C, Ponce S, et al. Current challenges in cancer treatment. Clin Ther. 2016;38(7):1551–1566. doi: 10.1016/j.clinthera.2016.03.026.
   PubMed Web of Science ®Google Scholar
• Compton C, Compton C. 2020. Cancer initiation, promotion, and progression and the acquisition of key behavioral traits. Cham: Springer.
   Google Scholar
• Arruebo M, Vilaboa N, Sáez-Gutierrez B, et al. Assessment of the evolution of cancer treatment therapies. Cancers. 2011;3(3):3279–3330. doi: 10.3390/cancers3033279.
   PubMedGoogle Scholar
• Raniolo S, Vindigni G, Ottaviani A, et al. Selective targeting and degradation of doxorubicin-loaded folate-functionalized DNA nanocages. Nanomedicine. 2018;14(4):1181–1190. doi: 10.1016/j.nano.2018.02.002.
   PubMed Web of Science ®Google Scholar
• Timucin AC, Basaga H, Kutuk O. Selective targeting of antiapoptotic BCL‐2 proteins in cancer. Med Res Rev. 2019;39(1):146–175. doi: 10.1002/med.21516.
   PubMed Web of Science ®Google Scholar
• Manish G, Vimukta S. Targeted drug delivery system: a review. Res J Chem Sci. 2011;1:135–138.
   Google Scholar
• Khan I, Khan M, Umar MN, et al. Nanobiotechnology and its applications in drug delivery system: a review. IET Nanobiotechnol. 2015;9(6):396–400. doi: 10.1049/iet-nbt.2014.0062.
   PubMed Web of Science ®Google Scholar
• Mohanraj V, Chen Y. Nanoparticles-a review. Trop J Pharm Res. 2007;5(1):561–573. doi: 10.4314/tjpr.v5i1.14634.
   Google Scholar
• Shan X, Gong X, Li J, et al. Current approaches of nanomedicines in the market and various stage of clinical translation. Acta Pharm Sin B. 2022;12(7):3028–3048. doi: 10.1016/j.apsb.2022.02.025.
   PubMed Web of Science ®Google Scholar
• Wolfram J, Ferrari M. Clinical cancer nanomedicine. Nano Today. 2019;25:85–98. doi: 10.1016/j.nantod.2019.02.005.
   PubMed Web of Science ®Google Scholar
• Gowd V, Ahmad A, Tarique M, et al. Advancement of cancer immunotherapy using nanoparticles-based nanomedicine. Semin Cancer Biol. 2022;86(Pt 2):624–644. doi: 10.1016/j.semcancer.2022.03.026.
   Google Scholar
• Jeanbart L, Swartz MA. Engineering opportunities in cancer immunotherapy. Proc Natl Acad Sci U S A. 2015;112(47):14467–14472. doi: 10.1073/pnas.1508516112.
   PubMed Web of Science ®Google Scholar
• Anselmo AC, Mitragotri S. Nanoparticles in the clinic: an update. Bioeng Transl Med. 2019;4(3):e10143. doi: 10.1002/btm2.10143.
   PubMed Web of Science ®Google Scholar
• Soares S, Sousa J, Pais A, et al. Nanomedicine: principles, properties, and regulatory issues. Front Chem. 2018;6:360. doi: 10.3389/fchem.2018.00360.
   PubMed Web of Science ®Google Scholar
• Allegra A, Gioacchino MD, Tonacci A, et al. Nanomedicine for immunotherapy targeting hematological malignancies: current approaches and perspective. Nanomaterials. 2021;11(11):2792. doi: 10.3390/nano11112792.
   Web of Science ®Google Scholar
• Irvine DJ, Dane EL. Enhancing cancer immunotherapy with nanomedicine. Nat Rev Immunol. 2020;20(5):321–334. doi: 10.1038/s41577-019-0269-6.
   PubMed Web of Science ®Google Scholar
• Tostanoski LH, Gosselin EA, Jewell CM. Engineering tolerance using biomaterials to target and control antigen presenting cells. Discov Med. 2016;21(117):403–410.
   PubMed Web of Science ®Google Scholar
• Gao Z, Zhang L, Sun Y. Nanotechnology applied to overcome tumor drug resistance. J Control Release. 2012;162(1):45–55. doi: 10.1016/j.jconrel.2012.05.051.
   PubMed Web of Science ®Google Scholar
• Steichen SD, Caldorera-Moore M, Peppas NA. A review of current nanoparticle and targeting moieties for the delivery of cancer therapeutics. Eur J Pharm Sci. 2013;48(3):416–427. doi: 10.1016/j.ejps.2012.12.006.
   PubMed Web of Science ®Google Scholar
• Waqar MA, Zaman M, Hameed H, et al. Formulation, characterization, and evaluation of β-Cyclodextrin functionalized hypericin loaded nanocarriers. ACS Omega. 2023;8(41):38191–38203. doi: 10.1021/acsomega.3c04444.
   PubMed Web of Science ®Google Scholar
• Zhang M, Liu E, Cui Y, et al. Nanotechnology-based combination therapy for overcoming multidrug-resistant cancer. Cancer Biol Med. 2017;14(3):212–227. doi: 10.20892/j.issn.2095-3941.2017.0054.
   PubMed Web of Science ®Google Scholar
• Waqar MA, Zaman M, Hameed H, et al. Ethosomes: a novel approach for the delivery of drug. IJPIHS. 2023;4:31–46.
   Google Scholar
• Bonacchi S, Genovese D, Juris R, et al. Luminescent silica nanoparticles: extending the frontiers of brightness. Angew Chem Int Ed Engl. 2011;50(18):4056–4066. doi: 10.1002/anie.201004996.
   PubMed Web of Science ®Google Scholar
• Rampazzo E, Voltan R, Petrizza L, et al. Proper design of silica nanoparticles combines high brightness, lack of cytotoxicity and efficient cell endocytosis. Nanoscale. 2013;5(17):7897–7905. doi: 10.1039/c3nr02563b.
   PubMed Web of Science ®Google Scholar
• Angelico R, Ceglie A, Colafemmina G, et al. Biocompatible lecithin organogels: Structure and phase equilibria. Langmuir. 2005;21(1):140–148. doi: 10.1021/la047974f.
   PubMed Web of Science ®Google Scholar
• Chong JY, Mulet X, Waddington LJ, et al. Steric stabilisation of self-assembled cubic lyotropic liquid crystalline nanoparticles: high throughput evaluation of triblock polyethylene oxide-polypropylene oxide-polyethylene oxide copolymers. Soft Matter. 2011;7(10):4768–4777. doi: 10.1039/c1sm05181d.
   Web of Science ®Google Scholar
• Hiwale P, Lampis S, Conti G, et al. In vitro release of lysozyme from gelatin microspheres: effect of cross-linking agents and thermos reversible gel as suspending medium. Biomacromolecules. 2011;12(9):3186–3193. doi: 10.1021/bm200679w.
   PubMed Web of Science ®Google Scholar
• Kumari A, Yadav SK, Yadav SC. Biodegradable polymeric nanoparticles based drug delivery systems. Colloids Surf B Biointerfaces. 2010;75(1):1–18. doi: 10.1016/j.colsurfb.2009.09.001.
   PubMed Web of Science ®Google Scholar
• Murgia S, Fadda P, Colafemmina G, et al. Characterization of the solutol® HS15/water phase diagram and the impact of the Δ9-tetrahydrocannabinol solubilization. J Colloid Interface Sci. 2013;390(1):129–136. doi: 10.1016/j.jcis.2012.08.068.
   PubMedGoogle Scholar
• Lee N, Hyeon T. Designed synthesis of uniformly sized iron oxide nanoparticles for efficient magnetic resonance imaging contrast agents. Chem Soc Rev. 2012;41(7):2575–2589. doi: 10.1039/c1cs15248c.
   PubMed Web of Science ®Google Scholar
• Ling D, Hyeon T. Iron oxide nanoparticles: chemical design of biocompatible iron oxide nanoparticles for medical applications (small 9–10/2013). Small. 2013;9(9–10):1449–1449. doi: 10.1002/smll.201370057.
   Web of Science ®Google Scholar
• Zhang Y, Sun Y, Xu X, et al. Synthesis, biodistribution, and microsingle photon emission computed tomography (SPECT) imaging study of technetium-99m labeled PEGylated dendrimer poly (amidoamine)(PAMAM)− folic acid conjugates. J Med Chem. 2010;53(8):3262–3272. doi: 10.1021/jm901910j.
   PubMed Web of Science ®Google Scholar
• Klostranec JM, Chan WC. Quantum dots in biological and biomedical research: recent progress and present challenges. Adv Mater. 2006;18(15):1953–1964. doi: 10.1002/adma.200500786.
   Web of Science ®Google Scholar
• Nam J, Won N, Bang J, et al. Surface engineering of inorganic nanoparticles for imaging and therapy. Adv Drug Deliv Rev. 2013;65(5):622–648. doi: 10.1016/j.addr.2012.08.015.
   PubMed Web of Science ®Google Scholar
• Zrazhevskiy P, Sena M, Gao X. Designing multifunctional quantum dots for bioimaging, detection, and drug delivery. Chem Soc Rev. 2010;39(11):4326–4354. doi: 10.1039/b915139g.
   PubMed Web of Science ®Google Scholar
• Gillies ER, Frechet JM. Dendrimers and dendritic polymers in drug delivery. Drug Discov Today. 2005;10(1):35–43. doi: 10.1016/S1359-6446(04)03276-3.
   PubMed Web of Science ®Google Scholar
• Svenson S, Tomalia DA. Dendrimers in biomedical applications—reflections on the field. Adv Drug Delivery Rev. 2012;64:102–115. doi: 10.1016/j.addr.2012.09.030.
   Web of Science ®Google Scholar
• Munir M, Zaman M, Waqar MA, et al. A comprehensive review on transethosomes as a novel vesicular approach for drug delivery through transdermal route. J Liposome Res. 2023:1–16. doi: 10.1080/08982104.2023.2221354.
   PubMed Web of Science ®Google Scholar
• Eloy JO, DE Souza MC, Petrilli R, et al. Liposomes as carriers of hydrophilic small molecule drugs: strategies to enhance encapsulation and delivery. Colloids Surf B Biointerfaces. 2014;123:345–363. doi: 10.1016/j.colsurfb.2014.09.029.
   PubMed Web of Science ®Google Scholar
• Tannous M, Caldera F, Hoti G, et al. Drug-encapsulated cyclodextrin nanosponges. Methods Mol Biol. 2021;2207:247–283.
   PubMedGoogle Scholar
• Fernandes M, Lopes I, Magalhães L, et al. Novel concept of exosome-like liposomes for the treatment of Alzheimer’s disease. J Control Release. 2021;336:130–143. doi: 10.1016/j.jconrel.2021.06.018.
   PubMed Web of Science ®Google Scholar
• Gao J, Fan K, Jin Y, et al. PEGylated lipid bilayer coated mesoporous silica nanoparticles co-delivery of paclitaxel and curcumin leads to increased tumor site drug accumulation and reduced tumor burden. Eur J Pharm Sci. 2019;140:105070. doi: 10.1016/j.ejps.2019.105070.
   PubMed Web of Science ®Google Scholar
• Jimenez J, Washington MA, Resnick JL, et al. A sustained release cysteamine microsphere/thermoresponsive gel eyedrop for corneal cystinosis improves drug stability. Drug Deliv Transl Res. 2021;11(5):2224–2238. doi: 10.1007/s13346-020-00890-6.
   PubMed Web of Science ®Google Scholar
• Suk JS, Xu Q, Kim N, et al. PEGylation as a strategy for improving nanoparticle-based drug and gene delivery. Adv Drug Deliv Rev. 2016;99(Pt A):28–51. doi: 10.1016/j.addr.2015.09.012.
   PubMed Web of Science ®Google Scholar
• Patel S, Patel M, Patel N. Need, development and application of virosomal system in medicine. IJRPNS. 2010;3(3):1065–1074. doi: 10.37285/ijpsn.2010.3.3.4.
   Google Scholar
• Tadwee IK, Gore S, Giradkar P. Advances in topical drug delivery system: a review. Int J Pharm Res All Sci. 2012;1:14–23.
   Google Scholar
• Alavi M, Karimi N, Safaei M. Application of various types of liposomes in drug delivery systems. Adv Pharm Bull. 2017;7(1):3–9. doi: 10.15171/apb.2017.002.
   PubMed Web of Science ®Google Scholar
• Gill B, Singh J, Sharma V, et al. Emulsomes: an emerging vesicular drug delivery system. Asian J Pharm. 2012;6(2):87. doi: 10.4103/0973-8398.102930.
   Google Scholar
• Semalty A, Semalty M, Rawat BS, et al. Pharmacosomes: the lipid-based new drug delivery system. Expert Opin Drug Deliv. 2009;6(6):599–612. doi: 10.1517/17425240902967607.
   PubMed Web of Science ®Google Scholar
• Saraf S, Rathi R, Deep Kaur C, et al. Sphingosomes a novel approach to vesicular drug delivery. Asian J Sci Res. 2010;4(1):1–15. doi: 10.3923/ajsr.2011.1.15.
   Google Scholar
• Jain S, Tiwary AK, Sapra B, et al. Formulation and evaluation of ethosomes for transdermal delivery of lamivudine. Aaps Pharmscitech. 2007;8(4):E111. doi: 10.1208/pt0804111.
   PubMed Web of Science ®Google Scholar
• Manosroi A, Jantrawut P, Khositsuntiwong N, et al. Novel elastic nanovesicles for cosmeceutical and pharmaceutical applications. Chiang Mai J Sci. 2009;36:168–178.
   Web of Science ®Google Scholar
• Romero EL, Morilla MJ. Highly deformable and highly fluid vesicles as potential drug delivery systems: theoretical and practical considerations. Int J Nanomed. 2013;8:3171–3186. doi: 10.2147/IJN.S33048.
   PubMed Web of Science ®Google Scholar
• Khalid H, Batool S, Din FU, et al. Macrophage targeting of nitazoxanide-loaded transethosomal gel in cutaneous leishmaniasis. R Soc Open Sci. 2022;9(10):220428. doi: 10.1098/rsos.220428.
   PubMed Web of Science ®Google Scholar
• Jain V, Lovanshi R, Khan AI. Formulation development and evaluation of niosomal gel of tazarotene for treatment of psoriasis. JMPAS. 2021;10(1):2664–2670. doi: 10.22270/jmpas.v10i1.1030.
   Google Scholar
• Jones DS, Moss GP. Themed issue: recent advances in transdermal drug delivery. J Pharm Pharmacol. 2010;62(6):669–670. doi: 10.1211/jpp.62.06.0001.
   PubMed Web of Science ®Google Scholar
• Pan X, Han K, Peng X, et al. Nanostructed cubosomes as advanced drug delivery system. Curr Pharm Des. 2013;19(35):6290–6297. doi: 10.2174/1381612811319350006.
   PubMed Web of Science ®Google Scholar
• Varghese R, Salvi S, Sood P, et al. Cubosomes in cancer drug delivery: a review. Colloid Interface Sci Commun. 2022;46:100561. doi: 10.1016/j.colcom.2021.100561.
   Web of Science ®Google Scholar
• Boge L, Hallstensson K, Ringstad L, et al. Cubosomes for topical delivery of the antimicrobial peptide LL-37. Eur J Pharm Biopharm. 2019;134:60–67. doi: 10.1016/j.ejpb.2018.11.009.
   PubMed Web of Science ®Google Scholar
• Rizwan SB, Boyd BJ. 2015. Cubosomes: structure, preparation and use as an antigen delivery system. In: Foged C, Rades T, Perrie Y, Hook S, editors. Subunit vaccine delivery. New York: Springer.
   Google Scholar
• Abdelkader H, Alani AW, Alany RG. Recent advances in non-ionic surfactant vesicles (niosomes): self-assembly, fabrication, characterization, drug delivery applications and limitations. Drug Deliv. 2014;21(2):87–100. doi: 10.3109/10717544.2013.838077.
   PubMed Web of Science ®Google Scholar
• Kaasgaard T, Drummond CJ. Ordered 2-D and 3-D nanostructured amphiphile self-assembly materials stable in excess solvent. Phys Chem Chem Phys. 2006;8(43):4957–4975. doi: 10.1039/b609510k.
   PubMed Web of Science ®Google Scholar
• Van Oss C, Good R, Chaudhury M. The role of van der Waals forces and hydrogen bonds in “hydrophobic interactions” between biopolymers and low energy surfaces. J Colloid Interface Sci. 1986;111(2):378–390. doi: 10.1016/0021-9797(86)90041-X.
   Web of Science ®Google Scholar
• Hyde ST. Identification of lyotropic liquid crystalline mesophases. In: Holmberg K, editor. Handbook of applied surface and colloid chemistry. Vol. 2. West Sussex: John Wiley & Sons; 2001; p. 299–332.
   Google Scholar
• Achouri D, Alhanout K, Piccerelle P, et al. Recent advances in ocular drug delivery. Drug Dev Ind Pharm. 2013;39(11):1599–1617. doi: 10.3109/03639045.2012.736515.
   PubMed Web of Science ®Google Scholar
• Barauskas J, Johnsson M, Tiberg F. Self-assembled lipid superstructures: beyond vesicles and liposomes. Nano Lett. 2005b;5(8):1615–1619. doi: 10.1021/nl050678i.
   PubMed Web of Science ®Google Scholar
• Rarokar NR, Saoji SD, Raut NA, et al. Nanostructured cubosomes in a thermoresponsive depot system: an alternative approach for the controlled delivery of docetaxel. AAPS Pharmscitech. 2016;17(2):436–445. doi: 10.1208/s12249-015-0369-y.
   PubMed Web of Science ®Google Scholar
• Seo SR, Kim J-C. Preparation of cubosomes containing gold nanoparticles and drug release behavior under light irradiation. J Control Release. 2013;172(1):e63–e64. doi: 10.1016/j.jconrel.2013.08.131.
   Web of Science ®Google Scholar
• Esposito E, Cortesi R, Drechsler M, et al. Cubosome dispersions as delivery systems for percutaneous administration of indomethacin. Pharm Res. 2005;22(12):2163–2173. doi: 10.1007/s11095-005-8176-x.
   PubMed Web of Science ®Google Scholar
• Demurtas D, Guichard P, Martiel I, et al. Direct visualization of dispersed lipid bicontinuous cubic phases by cryo-electron tomography. Nat Commun. 2015;6(1):8915. doi: 10.1038/ncomms9915.
   PubMedGoogle Scholar
• Huang Y, Gui S. Factors affecting the structure of lyotropic liquid crystals and the correlation between structure and drug diffusion. RSC Adv. 2018;8(13):6978–6987. doi: 10.1039/c7ra12008g.
   PubMed Web of Science ®Google Scholar
• Rarokar N, Khedekar P. Cubosomes: a vehicle for delivery of various therapeutic agents. MOJ Toxicol. 2018;4:19–21.
   Google Scholar
• Barauskas J, Johnsson M, Joabsson F, et al. Cubic phase nanoparticles (cubosome): principles for controlling size, structure, and stability. Langmuir. 2005a;21(6):2569–2577. doi: 10.1021/la047590p.
   PubMed Web of Science ®Google Scholar
• Anbarasan B, Grace XF, Shanmuganathan S. An overview of cubosomes—smart drug delivery system. Sri Ramachandra J. Med. 2015;8:1–4.
   Google Scholar
• Gan L, Han S, Shen J, et al. Self-assembled liquid crystalline nanoparticles as a novel ophthalmic delivery system for dexamethasone: improving preocular retention and ocular bioavailability. Int J Pharm. 2010;396(1-2):179–187. doi: 10.1016/j.ijpharm.2010.06.015.
   PubMed Web of Science ®Google Scholar
• Karami Z, Hamidi M. Cubosomes: remarkable drug delivery potential. Drug Discov Today. 2016;21(5):789–801. doi: 10.1016/j.drudis.2016.01.004.
   PubMed Web of Science ®Google Scholar
• Aleandri S, Bandera D, Mezzenga R, et al. Biotinylated cubosomes: a versatile tool for active targeting and codelivery of paclitaxel and a fluorescein-based lipid dye. Langmuir. 2015;31(46):12770–12776. doi: 10.1021/acs.langmuir.5b03469.
   PubMed Web of Science ®Google Scholar
• Clogston J, Caffrey M. Controlling release from the lipidic cubic phase. Amino acids, peptides, proteins and nucleic acids. J Control Release. 2005;107(1):97–111. doi: 10.1016/j.jconrel.2005.05.015.
   PubMed Web of Science ®Google Scholar
• Thadanki M, Kumari PS, Prabha KS. Overview of cubosomes: a nano particle. Int J Res Pharm Chem. 2011;1:535–541.
   Google Scholar
• Bhosale RR, Osmani RA, Harkare BR, et al. Cubosomes: the inimitable nanoparticulate drug carriers. Sch Acad J Pharm. 2013;2:481–486.
   Google Scholar
• Kulkarni CV, Wachter W, Iglesias-Salto G, et al. Monoolein: a magic lipid? Phys Chem Chem Phys. 2011;13(8):3004–3021. doi: 10.1039/c0cp01539c.
   PubMed Web of Science ®Google Scholar
• Chong JY, Mulet X, Boyd BJ, et al. 2015. Steric stabilizers for cubic phase lyotropic liquid crystal nanodispersions (cubosomes). APLBL. 21:131–187.
   Google Scholar
• Kaur SD, Singh G, Singh G, et al. Cubosomes as potential nanocarrier for drug delivery: a comprehensive review. JPRI. 2021;33:118–135. doi: 10.9734/jpri/2021/v33i31B31698.
   Google Scholar
• Van Dalsen L, Weichert D, Caffrey M. In meso crystallogenesis. Compatibility of the lipid cubic phase with the synthetic digitonin analogue, glyco-diosgenin. J Appl Crystallogr. 2020;53(Pt 2):530–535. doi: 10.1107/S1600576720002289.
   PubMedGoogle Scholar
• Iskandar WFNW, Salim M, Hashim R, et al. Stability of cubic phase and curvature tuning in the lyotropic system of branched chain galactose-based glycolipid by amphiphilic additives. Colloids Surf A. 2021;623:126697. doi: 10.1016/j.colsurfa.2021.126697.
   Google Scholar
• Akbar S, Anwar A, Ayish A, et al. Phytantriol based smart nano-carriers for drug delivery applications. Eur J Pharm Sci. 2017;101:31–42. doi: 10.1016/j.ejps.2017.01.035.
   PubMed Web of Science ®Google Scholar
• Wang X, Zhang Y, Huang J, et al. A novel phytantriol-based lyotropic liquid crystalline gel for efficient ophthalmic delivery of pilocarpine nitrate. AAPS PharmSciTech. 2019;20(1):1–14. doi: 10.1208/s12249-018-1248-0.
   Web of Science ®Google Scholar
• Yaghmur A, Mu H. Recent advances in drug delivery applications of cubosomes, hexosomes, and solid lipid nanoparticles. Acta Pharm Sin B. 2021;11(4):871–885. doi: 10.1016/j.apsb.2021.02.013.
   PubMed Web of Science ®Google Scholar
• Barkate AR, Gadekar DN. Cubosomes: the novel drug delivery system. World J Pharm Res. 2020;9:1170–1185.
   Google Scholar
• Tajik Ahmadabad B. 2017. Physicochemical characterization of novel functionalized lyotropic liquid crystalline carriers for therapeutic nucleotide delivery. Australia: University of Melbourne Parkville.
   Google Scholar
• Tan A, Hong L, Du JD, et al. Self‐assembled nanostructured lipid systems: is there a link between structure and cytotoxicity? Adv Sci. 2019;6(3):1801223. doi: 10.1002/advs.201801223.
   Web of Science ®Google Scholar
• Wörle G, Drechsler M, Koch MH, et al. Influence of composition and preparation parameters on the properties of aqueous monoolein dispersions. Int J Pharm. 2007;329(1-2):150–157. doi: 10.1016/j.ijpharm.2006.08.023.
   PubMedGoogle Scholar
• Van‘t Hag L, Gras SL, Conn CE, et al. Lyotropic liquid crystal engineering moving beyond binary compositional space–ordered nanostructured amphiphile self-assembly materials by design. Chem Soc Rev. 2017;46(10):2705–2731. doi: 10.1039/c6cs00663a.
   PubMed Web of Science ®Google Scholar
• Wadsten-Hindrichsen P, Bender J, Unga J, et al. Aqueous self-assembly of phytantriol in ternary systems: effect of monoolein, distearoylphosphatidylglycerol and three water-miscible solvents. J Colloid Interface Sci. 2007;315(2):701–713. doi: 10.1016/j.jcis.2007.07.011.
   PubMed Web of Science ®Google Scholar
• Esposito E, Eblovi N, Rasi S, et al. Lipid-based supramolecular systems for topical application: a preformulatory study. Aaps Pharmsci. 2003;5(4):E30–E76. doi: 10.1208/ps050430.
   PubMedGoogle Scholar
• Spicer PT, Hayden KL, Lynch ML, et al. Novel process for producing cubic liquid crystalline nanoparticles (cubosomes). Langmuir. 2001;17(19):5748–5756. doi: 10.1021/la010161w.
   Web of Science ®Google Scholar
• Mezzenga R, Meyer C, Servais C, et al. Shear rheology of lyotropic liquid crystals: a case study. Langmuir. 2005;21(8):3322–3333. doi: 10.1021/la046964b.
   PubMed Web of Science ®Google Scholar
• Um JY, Chung H, Kim KS, et al. In vitro cellular interaction and absorption of dispersed cubic particles. Int J Pharm. 2003;253(1-2):71–80. doi: 10.1016/s0378-5173(02)00673-7.
   PubMedGoogle Scholar
• Dandekar DV, Gaikar V. Hydrotropic extraction of curcuminoids from turmeric. Sep Sci Technol. 2003;38(5):1185–1215. doi: 10.1081/SS-120018130.
   Web of Science ®Google Scholar
• Maheshwari R, Chaturvedi S, Jain N. Novel application of hydrotropic solubilization in the analysis of some NSAIDs and their solid dosage forms. Indian J Pharm Sci. 2007;69(1):101. doi: 10.4103/0250-474X.32117.
   Google Scholar
• Nielsen LH, Rades T, Boyd B, et al. Microcontainers as an oral delivery system for spray dried cubosomes containing ovalbumin. Eur J Pharm Biopharm. 2017;118:13–20. doi: 10.1016/j.ejpb.2016.12.008.
   PubMed Web of Science ®Google Scholar
• Avachat AM, Parpani SS. Formulation and development of bicontinuous nanostructured liquid crystalline particles of efavirenz. Colloids Surf B Biointerfaces. 2015;126:87–97. doi: 10.1016/j.colsurfb.2014.12.014.
   PubMed Web of Science ®Google Scholar
• Spicer PT, Small WB, Small WB, et al. Dry powder precursors of cubic liquid crystalline nanoparticles (cubosomes). J Nanopart Res. 2002;4(4):297–311. doi: 10.1023/A:1021184216308.
   Web of Science ®Google Scholar
• Rosa A, Murgia S, Putzu D, et al. Monoolein-based cubosomes affect lipid profile in HeLa cells. Chem Phys Lipids. 2015;191:96–105. doi: 10.1016/j.chemphyslip.2015.08.017.
   PubMed Web of Science ®Google Scholar
• Murgia S, Falchi AM, Meli V, et al. Cubosome formulations stabilized by a dansyl-conjugated block copolymer for possible nanomedicine applications. Colloids Surf B Biointerfaces. 2015;129:87–94. doi: 10.1016/j.colsurfb.2015.03.025.
   PubMed Web of Science ®Google Scholar
• Mansour M, EL Ezz TAA, Fattoh FN, et al. Delineating the usage of dexamethasone-loaded cubosomes as a therapeutic armamentarium for hearing loss versus its protective effect: in-vitro and in-vivo animal study. J Drug Deliv Sci Technol. 2021;61:102244. doi: 10.1016/j.jddst.2020.102244.
   Web of Science ®Google Scholar
• Ou N, Sun Y, Zhou S, et al. Evaluation of optimum conditions for achyranthes bidentata polysaccharides encapsulated in cubosomes and immunological activity in vitro. Int J Biol Macromol. 2018;109:748–760. doi: 10.1016/j.ijbiomac.2017.11.064.
   PubMed Web of Science ®Google Scholar
• Abdelrahman FE, Elsayed I, Gad MK, et al. Investigating the cubosomal ability for transnasal brain targeting: in vitro optimization, ex vivo permeation and in vivo biodistribution. Int J Pharm. 2015;490(1-2):281–291. doi: 10.1016/j.ijpharm.2015.05.064.
   PubMed Web of Science ®Google Scholar
• Janakiraman K, Krishnaswami V, Sethuraman V, et al. Development of methotrexate-loaded cubosomes with improved skin permeation for the topical treatment of rheumatoid arthritis. Appl Nanosci. 2019;9(8):1781–1796. doi: 10.1007/s13204-019-00976-9.
   Web of Science ®Google Scholar
• Nasr M, Dawoud M. Sorbitol based powder precursor of cubosomes as an oral delivery system for improved bioavailability of poorly water soluble drugs. J Drug Delivery Sci Technol. 2016;35:106–113. doi: 10.1016/j.jddst.2016.06.011.
   Web of Science ®Google Scholar
• VON Halling Laier C, Gibson B, VAN DE Weert M, et al. Spray dried cubosomes with ovalbumin and Quil-A as a nanoparticulate dry powder vaccine formulation. Int J Pharm. 2018;550(1-2):35–44. doi: 10.1016/j.ijpharm.2018.08.036.
   PubMedGoogle Scholar
• Mertins O, Mathews PD, Angelova A. Advances in the design of ph-sensitive cubosome liquid crystalline nanocarriers for drug delivery applications. Nanomaterials. 2020;10(5):963. doi: 10.3390/nano10050963.
   Web of Science ®Google Scholar
• Malheiros B, DE Castro RD, Lotierzo MC, et al. Influence of hexadecylphosphocholine (miltefosine) in phytantriol-based cubosomes: a structural investigation. Colloids Surf A. 2022;632:127720. doi: 10.1016/j.colsurfa.2021.127720.
   Google Scholar
• Chen H, Fan Y, Zhang N, et al. Fluorescent polymer cubosomes and hexosomes with aggregation-induced emission. Chem Sci. 2021;12(15):5495–5504. doi: 10.1039/d1sc00270h.
   PubMed Web of Science ®Google Scholar
• Almoshari Y. Development, therapeutic evaluation and theranostic applications of cubosomes on cancers: an updated review. Pharmaceutics. 2022;14(3):600. doi: 10.3390/pharmaceutics14030600.
   PubMed Web of Science ®Google Scholar
• Oliveira C, Ferreira CJ, Sousa M, et al. A versatile nanocarrier—cubosomes, characterization, and applications. Nanomaterials. 2022;12(13):2224. doi: 10.3390/nano12132224.
   Web of Science ®Google Scholar
• Palma AS, Casadei BR, Lotierzo MC, et al. A short review on the applicability and use of cubosomes as nanocarriers. Biophys Rev. 2023;15(4):553–567. doi: 10.1007/s12551-023-01089-y.
   PubMedGoogle Scholar
• Zur Mühlen A, Schwarz C, Mehnert W. Solid lipid nanoparticles (SLN) for controlled drug delivery–drug release and release mechanism. Eur J Pharm Biopharm. 1998;45(2):149–155. doi: 10.1016/s0939-6411(97)00150-1.
   PubMed Web of Science ®Google Scholar
• Fong C, Zhai J, Drummond CJ, et al. Micellar Fd3m cubosomes from monoolein–long chain unsaturated fatty acid mixtures: Stability on temperature and pH response. J Colloid Interface Sci. 2020;566:98–106. doi: 10.1016/j.jcis.2020.01.041.
   PubMed Web of Science ®Google Scholar
• Shah J, Nair AB, Jacob S, et al. Nanoemulsion based vehicle for effective ocular delivery of moxifloxacin using experimental design and pharmacokinetic study in rabbits. Pharmaceutics. 2019;11(5):230. doi: 10.3390/pharmaceutics11050230.
   PubMed Web of Science ®Google Scholar
• Rao SV, Sravya BN, Padmalatha K. A review on cubosome: the novel drug delivery system. GSC Biol Pharm Sci. 2018;5:76–81.
   Google Scholar
• Almoshari Y, Alam MI, Bakkari MA, et al. Formulation, characterization, and evaluation of doxorubicin-loaded cubosome as a cytotoxic potentiator against HCT-116 colorectal cancer cells. IJPER. 2022;56(3):723–731. doi: 10.5530/ijper.56.3.121.
   Google Scholar
• Khan S, Madni A, Rahim MA, et al. Enhanced in vitro release and permeability of glibenclamide by proliposomes: Development, characterization and histopathological evaluation. J Drug Delivery Sci Technol. 2021;63:102450. doi: 10.1016/j.jddst.2021.102450.
   Web of Science ®Google Scholar
• Zhai J, Yap SL, Drummond CJ, et al. Controlling the pH dependent transition between monoolein Fd3m micellar cubosomes and hexosomes using fatty acetate and fatty acid additive mixtures. J Colloid Interface Sci. 2022;607(Pt 1):848–856. doi: 10.1016/j.jcis.2021.08.173.
   PubMedGoogle Scholar
• Latif MS, Al-Harbi FF, Nawaz A, et al. Formulation and evaluation of hydrophilic polymer based methotrexate patches: in vitro and in vivo characterization. Polymers. 2022;14(7):1310. doi: 10.3390/polym14071310.
   PubMed Web of Science ®Google Scholar
• Cytryniak A, Nazaruk E, Bilewicz R, et al. Lipidic cubic-phase nanoparticles (cubosomes) loaded with doxorubicin and labeled with 177Lu as a potential tool for combined chemo and internal radiotherapy for cancers. Nanomaterials. 2020;10(11):2272. doi: 10.3390/nano10112272.
   Web of Science ®Google Scholar
• Cisterna BA, Kamaly N, Choi WI, et al. Targeted nanoparticles for colorectal cancer. Nanomedicine. 2016;11(18):2443–2456. doi: 10.2217/nnm-2016-0194.
   PubMed Web of Science ®Google Scholar
• Hu C-MJ, Aryal S, Zhang L. Nanoparticle-assisted combination therapies for effective cancer treatment. Ther Deliv. 2010;1(2):323–334. doi: 10.4155/tde.10.13.
   PubMedGoogle Scholar
• Barani M, Bilal M, Rahdar A, et al. Nanodiagnosis and nanotreatment of colorectal cancer: an overview. J Nanopart Res. 2021;23(1):25. doi: 10.1007/s11051-020-05129-6.
   Web of Science ®Google Scholar
• Saber MM, Al-Mahallawi AM, Nassar NN, et al. Targeting colorectal cancer cell metabolism through development of cisplatin and metformin nano-cubosomes. BMC Cancer. 2018;18(1):822. doi: 10.1186/s12885-018-4727-5.
   PubMedGoogle Scholar
• Magdy M, Almahallawi A, Nassar N, et al. Pluronic based cubosomes enhance metformin cytotoxicity in Colon cancer cell lines. Clin Ther. 2017;39(8):e27. doi: 10.1016/j.clinthera.2017.05.082.
   Google Scholar
• Radbeh Z, Asefi N, Hamishehkar H, et al. Novel carriers ensuring enhanced anti-cancer activity of cornus mas (cornelian cherry) bioactive compounds. Biomed Pharmacother. 2020;125:109906. doi: 10.1016/j.biopha.2020.109906.
   PubMed Web of Science ®Google Scholar
• Jin X, Zhang Z-H, Li S-L, et al. A nanostructured liquid crystalline formulation of 20 (S)-protopanaxadiol with improved oral absorption. Fitoterapia. 2013;84:64–71. doi: 10.1016/j.fitote.2012.09.013.
   PubMed Web of Science ®Google Scholar
• Dorling L, Carvalho S, Allen J, et al. Breast cancer risk genes: association analysis in more than 113,000 women. N Engl J Med. 2021;384(5):428–439. doi: 10.1056/NEJMoa1913948.
   PubMed Web of Science ®Google Scholar
• Hussain Z, Khan JA, Murtaza S. Nanotechnology: an emerging therapeutic option for breast cancer. Crit Rev Eukaryot Gene Expr. 2018;28:163–175.
   Web of Science ®Google Scholar
• Astolfi P, Giorgini E, Gambini V, et al. Lyotropic liquid-crystalline nanosystems as drug delivery agents for 5-fluorouracil: structure and cytotoxicity. Langmuir. 2017;33(43):12369–12378. doi: 10.1021/acs.langmuir.7b03173.
   PubMed Web of Science ®Google Scholar
• Mehanna MM, Sarieddine R, Alwattar JK, et al. Anticancer activity of thymoquinone cubic phase nanoparticles against human breast cancer: formulation, cytotoxicity and subcellular localization. Int J Nanomed. 2020;15:9557–9570. doi: 10.2147/IJN.S263797.
   PubMed Web of Science ®Google Scholar
• Leiter U, Keim U, Garbe C. Epidemiology of skin cancer: update 2019. Adv Exp Med Biol. 2020;1268:123–139.
   PubMed Web of Science ®Google Scholar
• Kalal BS, Upadhya D, Pai VR. Chemotherapy resistance mechanisms in advanced skin cancer. Oncol Rev. 2017;11(1):326. doi: 10.4081/oncol.2017.[28382191.
   PubMedGoogle Scholar
• Zhai J, Tan FH, Luwor RB, et al. In vitro and in vivo toxicity and biodistribution of paclitaxel-loaded cubosomes as a drug delivery nanocarrier: a case study using an A431 skin cancer xenograft model. ACS Appl Bio Mater. 2020;3(7):4198–4207. doi: 10.1021/acsabm.0c00269.
   PubMedGoogle Scholar
• Kurangi B, Jalalpure S, Jagwani S. Formulation and evaluation of resveratrol loaded cubosomal nanoformulation for topical delivery. Curr Drug Deliv. 2021;18(5):607–619. doi: 10.2174/1567201817666200902150646.
   PubMed Web of Science ®Google Scholar
• Yuan Y-G, Peng Q-L, Gurunathan S. Silver nanoparticles enhance the apoptotic potential of gemcitabine in human ovarian cancer cells: combination therapy for effective cancer treatment. Int J Nanomed. 2017;12:6487–6502. doi: 10.2147/IJN.S135482.
   PubMed Web of Science ®Google Scholar
• Fahmy UA, Fahmy O, Alhakamy NA. Optimized icariin cubosomes exhibit augmented cytotoxicity against SKOV-3 ovarian cancer cells. Pharmaceutics. 2020;13(1):20. doi: 10.3390/pharmaceutics13010020.
   PubMed Web of Science ®Google Scholar
• Zhai J, Luwor RB, Ahmed N, et al. Paclitaxel-loaded self-assembled lipid nanoparticles as targeted drug delivery systems for the treatment of aggressive ovarian cancer. ACS Appl Mater Interfaces. 2018;10(30):25174–25185. doi: 10.1021/acsami.8b08125.
   PubMed Web of Science ®Google Scholar
• Shafabakhsh R, Reiter RJ, Mirzaei H, et al. Melatonin: a new inhibitor agent for cervical cancer treatment. J Cell Physiol. 2019;234(12):21670–21682. doi: 10.1002/jcp.28865.
   PubMed Web of Science ®Google Scholar
• Bade BC, Cruz CSD. Lung cancer 2020: epidemiology, etiology, and prevention. Clin Chest Med. 2020;41(1):1–24. doi: 10.1016/j.ccm.2019.10.001.
   PubMed Web of Science ®Google Scholar
• Sharma P, Mehta M, Dhanjal DS, et al. Emerging trends in the novel drug delivery approaches for the treatment of lung cancer. Chem Biol Interact. 2019;309:108720. doi: 10.1016/j.cbi.2019.06.033.
   PubMed Web of Science ®Google Scholar
• Patil SM, Sawant SS, Kunda NK. Inhalable bedaquiline-loaded cubosomes for the treatment of non-small cell lung cancer (NSCLC). Int J Pharm. 2021;607:121046. doi: 10.1016/j.ijpharm.2021.121046.
   PubMedGoogle Scholar
• Sethuraman V, Janakiraman K, Krishnaswami V, et al. pH responsive delivery of lumefantrine with calcium phosphate nanoparticles loaded lipidic cubosomes for the site specific treatment of lung cancer. Chem Phys Lipids. 2019;224:104763. doi: 10.1016/j.chemphyslip.2019.03.016.
   PubMed Web of Science ®Google Scholar
• Anwanwan D, Singh SK, Singh S, et al. Challenges in liver cancer and possible treatment approaches. Biochim Biophys Acta Rev Cancer. 2020;1873(1):188314. doi: 10.1016/j.bbcan.2019.188314.
   PubMed Web of Science ®Google Scholar
• Nasr M, Ghorab MK, Abdelazem A. In vitro and in vivo evaluation of cubosomes containing 5-fluorouracil for liver targeting. Acta Pharm Sin B. 2015;5(1):79–88. doi: 10.1016/j.apsb.2014.12.001.
   PubMed Web of Science ®Google Scholar
• Saber S, Nasr M, Saad AS, et al. Albendazole-loaded cubosomes interrupt the ERK1/2-HIF-1α-p300/CREB axis in mice intoxicated with diethylnitrosamine: a new paradigm in drug repurposing for the inhibition of hepatocellular carcinoma progression. Biomed Pharmacother. 2021;142:112029. doi: 10.1016/j.biopha.2021.112029.
   PubMed Web of Science ®Google Scholar
• Abdel-Bar HM, Abd EL Basset Sanad R. Endocytic pathways of optimized resveratrol cubosomes capturing into human hepatoma cells. Biomed Pharmacother. 2017;93:561–569. doi: 10.1016/j.biopha.2017.06.093.
   PubMed Web of Science ®Google Scholar
• Luo Q, Lin T, Zhang CY, et al. A novel glyceryl monoolein-bearing cubosomes for gambogenic acid: preparation, cytotoxicity and intracellular uptake. Int J Pharm. 2015;493(1-2):30–39. doi: 10.1016/j.ijpharm.2015.07.036.
   PubMed Web of Science ®Google Scholar
• Hasan M, Khatun A, Fukuta T, et al. Noninvasive transdermal delivery of liposomes by weak electric current. Adv Drug Deliv Rev. 2020;154–155:227–235. doi: 10.1016/j.addr.2020.06.016.
   PubMed Web of Science ®Google Scholar